Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $202,680.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, April 25th. The stock was sold at an average price of $16.89, for a total value of $202,680.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Samuel Kintz also recently made the following trade(s):

• On Thursday, April 11th, Samuel Kintz sold 47,709 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total transaction of $1,194,633.36.
• On Monday, March 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $17.56, for a total transaction of $210,720.00.

Enliven Therapeutics Price Performance

Shares of ELVN traded up $0.61 during trading hours on Monday, hitting $17.79. 283,528 shares of the stock were exchanged, compared to its average volume of 230,641. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $26.00. The business has a 50-day moving average of $17.12 and a 200-day moving average of $14.50. The firm has a market capitalization of $832.75 million, a P/E ratio of -8.12 and a beta of 1.06.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.09. As a group, analysts forecast that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. AJOVista LLC bought a new position in shares of Enliven Therapeutics in the fourth quarter valued at $28,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Enliven Therapeutics during the fourth quarter valued at about $66,000. Exchange Traded Concepts LLC lifted its position in shares of Enliven Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after purchasing an additional 2,208 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Enliven Therapeutics during the third quarter valued at about $157,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Enliven Therapeutics by 9.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after buying an additional 1,029 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Mizuho initiated coverage on shares of Enliven Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price target for the company.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.